Surrozen Posts $129.7M Q3 Net Loss as Operating Expenses Hit $17.6M
SRZN has more than doubled off its 52-week low of $11.51 on light trading volume (0.2× avg).
Summary
Surrozen reported a Q3 net loss of $129.724 million against operating expenses of $17.642 million, with an operating loss of $17.642 million, and said its runway extends into 2029. The gap between the operating loss and the net loss points to large non-cash items below the operating line, consistent with the fair-value adjustments that drove the $127.5 million net loss in Q1. Cash burn remains the core issue: the company has been leaning on its $50 million at-the-market program and the roughly $95.1 million raised from the final tranche of its March 2025 private placement, closed October 20. The operating expense base of about $17.6 million a quarter is the number that matters for runway, and it is running well above the revenue-less biotech's ability to self-fund. The SZN-8141 diabetic macular edema program, whose IND cleared October 2, is the main value driver and the main consumer of that cash.
At the time of this announcement, SRZN was trading at $32.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $376.1M. The 52-week trading range was $11.51 to $37.83. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.